View Future GrowthGerresheimer 過去の業績過去 基準チェック /06Gerresheimerの収益は年間平均-23.5%の割合で減少していますが、 Life Sciences業界の収益は年間 減少しています。収益は年間3.5% 9.8%割合で 増加しています。主要情報-23.51%収益成長率-24.65%EPS成長率Life Sciences 業界の成長21.51%収益成長率9.83%株主資本利益率-28.79%ネット・マージン-13.80%次回の業績アップデート14 Jul 2026最近の業績更新お知らせ • Oct 16+ 3 more updatesGerresheimer AG to Report Fiscal Year 2025 Results on Feb 26, 2026Gerresheimer AG announced that they will report fiscal year 2025 results at 1:25 PM, Central European Standard Time on Feb 26, 2026お知らせ • Feb 20Gerresheimer AG to Report Q3, 2025 Results on Oct 10, 2025Gerresheimer AG announced that they will report Q3, 2025 results on Oct 10, 2025お知らせ • Sep 28+ 2 more updatesGerresheimer AG to Report Q2, 2024 Results on Jul 11, 2024Gerresheimer AG announced that they will report Q2, 2024 results on Jul 11, 2024お知らせ • Dec 28+ 1 more updateGerresheimer AG to Report Q3, 2023 Results on Oct 05, 2023Gerresheimer AG announced that they will report Q3, 2023 results on Oct 05, 2023お知らせ • Jul 13+ 2 more updatesGerresheimer AG to Report Fiscal Year 2022 Results on Feb 17, 2023Gerresheimer AG announced that they will report fiscal year 2022 results on Feb 17, 2023すべての更新を表示Recent updatesお知らせ • Jul 01Gerresheimer AG Updates Its Earnings Guidance for 2026Gerresheimer AG updated its earnings guidance for 2026. Due to the challenging economic environment, some project delays on the part of customers, and operational challenges — among others those related to production ramp-ups — the company is adjusting its guidance for financial year 2026. Before M&A and refinancing activities, the Group now expects revenues to be in the lower half of the EUR 2.3 billion to EUR 2.4 billion range (previously EUR 2.3 billion to EUR 2.4 billion).お知らせ • Apr 11Gerresheimer AG(XTRA:GXI) dropped from Germany SDAX (Total Return) IndexGerresheimer AG has been dropped from the Germany SDAX (Total Return) Indexお知らせ • Nov 22Gerresheimer AG Announces Supervisory Board ChangesKlaus Röhrig, co-founder and Co-Chief Investment Officer of the Active Ownership Group, has been appointed to the Supervisory Board of Gerresheimer AG until the next Annual General Meeting in June 2026. He succeeds Dr. Dorothea Wenzel, who made her position available to reflect the changed shareholder structure of the company in the composition of the Supervisory Board. With his appointment, Klaus Röhrig also assumes the duties of Dr. Dorothea Wenzel on the Audit Committee of Gerresheimer AG. Klaus Röhrig will stand for election to the Supervisory Board at the next Annual General Meeting on June 3, 2026. In total, four shareholder representatives will be up for election at the next Annual General Meeting of Gerresheimer AG’s co-determined Supervisory Board.お知らせ • Oct 16+ 3 more updatesGerresheimer AG to Report Fiscal Year 2025 Results on Feb 26, 2026Gerresheimer AG announced that they will report fiscal year 2025 results at 1:25 PM, Central European Standard Time on Feb 26, 2026お知らせ • Oct 14Gerresheimer Ag Announces Fda Grants Approval of Sq Innovation's Lasix®? OnyuGerresheimer announced that the US Food and Drug Administration (FDA) granted SQ Innovation approval for Lasix ONYU for treatment of edema in congestive heart failure. Lasix ONYU is a combination product consisting of a novel high-concentration formulation of the diuretic furosemide and the Gerresheimer on-body drug delivery device (infusor). It was developed to enable subcutaneous infusion of furosemide at home for selected patients, as prescribed by a clinician without the need for a healthcare professional to administer the drug. The cartridge-based infusor was designed and developed by Gerresheimer based on its proprietary infusor platform for subcutaneous drug delivery. Gerresheimer also manages production of the device as a full-service solution provider. First products of Lasix ONYU are expected to be available on the market already in 2025. The FDA's approval of the combination product demonstrates Gerresheimer's innovative strength and its strong partnership with customers, from product design to large-scale manufacturing. Device based on Gerresheimer's innovative micropump technology: The cartridge-based infus or was designed and developed by Ger Resheimer based on its proprietary infUSor platform for subcutaneous Drug delivery. The core technology is an innovative micropump which enables controlled, precise administration of a drug product according to a defined therapy regimen. Designed with patient comfort and the environment in mind The lightweight, compact device is patched onto the patient's body, making it comfortable for the patient to wear while the drug is gently infused. The reusable component, which is rated for delivery of 48 treatments with diuretic furosemides, is recyclable. Because only the disposable unit requires sterilization, radiation can be used instead of chemical sterilization, and no electronic components end up in medical waste. This two-component concept was developed in line with Gerresheimer's EcoDesign principles, which aim to increase product lifespan and reduce waste. Reducing total cost of care and improving patients' quality of life. The combination product Lasix ONYU also opens up possibilities to reduce the total cost of care. The two-component design results in a lower cost per treatment, because only the disposable part of the device needs to be replaced. Most importantly, the infusor allows for home treatment, reducing the length of hospital stay or avoiding the need for hospitalization for intravenous diuretic administration altogether. First products expected to be available already in 2025 In addition to Gerresheimer's role in design and development, Gerresheimer also manages production the device as a full- service solution provider. The disposable unit for the infusor is, for example, produced at the Gerresheimer facility in Wackersdorf, Germany, on a high-capacity semi-automated line. Production commenced earlier this year in anticipation of approval and first products are expected to be available before the end of the year.お知らせ • Oct 10+ 2 more updatesGerresheimer AG Appoints Hans-Norbert Topp as Head of Combined Moulded Glass Business UnitGerresheimer AG announced that as part of the integration of Bormioli Pharma into the Gerresheimer Group, Gerresheimer has already begun to establish the combined Moulded Glass business as a global, independent unit. Hans-Norbert Topp, an internationally experienced manager with a proven track record, has been appointed to head the business unit.お知らせ • Aug 22Active Ownership Wants Review at Gerresheimer After Taking StakeOn August 21, 2025, Active Ownership announced that it saw major potential for value creation at Gerresheimer AG and called for a strategic review. Active Ownership expressly welcomes the planned sale process for the moulded glass division and calls for a swift settlement in order to strengthen the Company's cash flow and reduce debt. Active Ownership also stated that further key measures should include additional portfolio optimization and the implementation of an efficiency programme, particularly through cost reductions in administration and business units. Active Ownership added that this would improve the return on the Company's sales by five percentage points, while also calling for the creation of a strategy committee to review all of the Company's ongoing projects.お知らせ • Jul 11Gerresheimer AG Provides Revenue Guidance for the Second Half of 2025Gerresheimer AG provided revenue guidance for the second half of 2025. In the second half of 2025, Gerresheimer expects stronger growth again based on production ramp-ups and a good order intake, and anticipates organic revenue growth of 0 – 2% compared to the previous year.お知らせ • Jun 06Asset Value Investors Calls for Changes at Gerresheimer AGOn June 5, 2025, Asset Value Investors Limited called upon Gerresheimer AG to take steps to restore its market value, a move partially supported by another top 30 investor. Asset Value Investors expressed its views that new financial leadership is needed to restore the Company's relationship and credibility with investors, it said in an open letter to the Company. Asset Value Investors also urged the Company to establish a capital allocation committee and exit its moulded glass business as soon as possible. Union Investment, which holds a 0.9% stake in the Company, said it backed the calls for new leadership and a sale of the moulded glass business but did not see a need for a capital allocation committee.お知らせ • Jun 05+ 1 more updateGerresheimer AG Revises Earnings Guidance for the Financial Year 2025Gerresheimer AG revised earnings guidance for the financial year 2025. For the financial year, the company expects organic revenue growth to be 1% to 2% compared to the previous year (previously: 3% to 5%).お知らせ • Apr 24Gerresheimer AG, Annual General Meeting, Jun 05, 2025Gerresheimer AG, Annual General Meeting, Jun 05, 2025, at 10:00 W. Europe Standard Time.お知らせ • Apr 11Gerresheimer AG Confirms Earnings Guidance for the Mid-Term of the Fiscal Year 2025Gerresheimer AG confirmed earnings guidance for the mid-term of the fiscal year 2025. For the mid-term, the company expects organic revenue growth 8% - 10% CAGR.お知らせ • Mar 13Warburg Pincus, KKR Consortium Reportedly in Talks to Buy GerresheimerA consortium consisting of Warburg Pincus LLC and KKR & Co. Inc. (NYSE:KKR) are in talks to acquire Gerresheimer AG (ETR:GXI), the German maker of packaging for drugs and cosmetics, according to people familiar with the matter. The private equity firms emerged as the frontrunner after they teamed up and other potential bidders including Bain Capital dropped, the people said, asking not to be identified discussing confidential information. The Warburg Pincus-KKR consortium is unlikely to offer a significant premium to Gerresheimer’s current price and there are still major hurdles to a deal, some of the people said. While the talks are advanced, any final agreement could take weeks and a deal could still fall apart, they added. Representatives for Gerresheimer, Warburg Pincus, KKR and Bain declined to comment.お知らせ • Feb 27Gerresheimer AG announces Annual dividend, payable on June 10, 2025Gerresheimer AG announced Annual dividend of EUR 1.2500 per share payable on June 10, 2025, ex-date on June 06, 2025 and record date on June 09, 2025.お知らせ • Feb 21Phillips-Medisize, Bain Capital Reportedly Eye GerresheimerUS medical solutions company Phillips-Medisize (Phillips-Medisize, LLC) and buyout firm Bain Capital (Bain Capital, LP) are among potential bidders for Gerresheimer AG (XTRA:GXI), the German maker of packaging for drugs and cosmetics, according to people familiar with the matter. The firms join other suitors that have been evaluating possible offers for part or all of Gerresheimer, the people said, asking not to be identified because the information is private.お知らせ • Feb 20Gerresheimer AG to Report Q3, 2025 Results on Oct 10, 2025Gerresheimer AG announced that they will report Q3, 2025 results on Oct 10, 2025お知らせ • Feb 11Gerresheimer Discussing Takeover with Private Equity InvestorsGerman pill bottles and syringes maker Gerresheimer AG (XTRA:GXI) said on February 07, 2025 that it is in early-stage talks with private equity investors over a potential takeover, confirming a media report. The private equity firms have expressed, on an informal and non-binding basis, their interest to explore a possible public takeover offer for Gerresheimer, the company said. The discussions are still in a very preliminary stage and it is not certain at this point whether an offer will actually be made, the firm added, without disclosing further details. The statement was made after news agency Bloomberg previously reported that private equity firms Warburg Pincus LLC, EQT AB (publ) (OM:EQT) and KKR & Co. Inc. (NYSE:KKR) among other suitors have shown interest in the German pill bottles and syringes maker.お知らせ • Apr 11Gerresheimer AG Provides Earnings Guidance for the Year 2024 and 2025Gerresheimer AG provided earnings guidance for the year 2024 and 2025. For the year 2024, the company expects revenue growth of 5% to 10%.For the year 2025, the company expects revenue growth of 10% to 15%.お知らせ • Dec 06+ 1 more updateGerresheimer AG, Annual General Meeting, Jun 05, 2024Gerresheimer AG, Annual General Meeting, Jun 05, 2024.お知らせ • Oct 06Gerresheimer AG Provides Earnings Guidance for Full Year 2023Gerresheimer AG provided earnings guidance for full year 2023. For the year, the company expects Organic revenue growth: at least 10% and Medium-term guidance (for group level, currency-adjusted), Organic revenue growth: at least 10%.お知らせ • Sep 28+ 2 more updatesGerresheimer AG to Report Q2, 2024 Results on Jul 11, 2024Gerresheimer AG announced that they will report Q2, 2024 results on Jul 11, 2024お知らせ • Jul 06Gerresheimer Ag Provides Revenue Guidance for Full Year 2023Gerresheimer AG provided revenue guidance for full year 2023. For the year, the company expects Organic revenue growth: at least 10% and Medium-term guidance (for group level, currency-adjusted), Organic revenue growth: at least 10%.お知らせ • Jun 08Gerresheimer AG Announces Dividend for the Financial Year 2022, Payable on June 12, 2023Gerresheimer AG announced a dividend of EUR 1.25 for the financial year 2022. The dividend is to be paid out on June 12, 2023.お知らせ • Dec 28+ 1 more updateGerresheimer AG to Report Q3, 2023 Results on Oct 05, 2023Gerresheimer AG announced that they will report Q3, 2023 results on Oct 05, 2023お知らせ • Jul 13+ 2 more updatesGerresheimer AG to Report Fiscal Year 2022 Results on Feb 17, 2023Gerresheimer AG announced that they will report fiscal year 2022 results on Feb 17, 2023収支内訳Gerresheimer の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:GRRM.F 収益、費用、利益 ( )EUR Millions日付収益収益G+A経費研究開発費30 Nov 252,321-3204392231 Aug 252,250234152231 May 252,188634092128 Feb 252,090793972330 Nov 241,991823872431 Aug 242,0121143681931 May 242,0021153681529 Feb 241,9991173721330 Nov 231,9901163731631 Aug 231,9741073801931 May 231,9591073782328 Feb 231,904973682630 Nov 221,817963512231 Aug 221,725913361731 May 221,634823141528 Feb 221,566852981230 Nov 211,498842851031 Aug 211,46586278831 May 211,43293272828 Feb 211,41894272930 Nov 201,41989275831 Aug 201,385-25275731 May 201,394-32275529 Feb 201,388-14273130 Nov 191,39281273031 Aug 191,415207273031 May 191,410207270028 Feb 191,386179265030 Nov 181,368129259031 Aug 181,351124258031 May 181,329131256028 Feb 181,336137258030 Nov 171,348101259031 Aug 171,33149257031 May 171,35053259028 Feb 171,35856258030 Nov 161,37558259031 Aug 161,299118243031 May 161,292106240029 Feb 161,30199238030 Nov 151,28396231031 Aug 151,335692360質の高い収益: GRRM.Fは現在利益が出ていません。利益率の向上: GRRM.Fは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: GRRM.Fは利益が出ておらず、過去 5 年間で損失は年間23.5%の割合で増加しています。成長の加速: GRRM.Fの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: GRRM.Fは利益が出ていないため、過去 1 年間の収益成長をLife Sciences業界 ( 5.2% ) と比較することは困難です。株主資本利益率高いROE: GRRM.Fは現在利益が出ていないため、自己資本利益率 ( -28.79% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/06 19:44終値2026/06/30 00:00収益2025/11/30年間収益2025/11/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Gerresheimer AG 11 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。30 アナリスト機関Gaurav JainBarclaysJonathon UnwinBarclaysPallav MittalBarclays27 その他のアナリストを表示
お知らせ • Oct 16+ 3 more updatesGerresheimer AG to Report Fiscal Year 2025 Results on Feb 26, 2026Gerresheimer AG announced that they will report fiscal year 2025 results at 1:25 PM, Central European Standard Time on Feb 26, 2026
お知らせ • Feb 20Gerresheimer AG to Report Q3, 2025 Results on Oct 10, 2025Gerresheimer AG announced that they will report Q3, 2025 results on Oct 10, 2025
お知らせ • Sep 28+ 2 more updatesGerresheimer AG to Report Q2, 2024 Results on Jul 11, 2024Gerresheimer AG announced that they will report Q2, 2024 results on Jul 11, 2024
お知らせ • Dec 28+ 1 more updateGerresheimer AG to Report Q3, 2023 Results on Oct 05, 2023Gerresheimer AG announced that they will report Q3, 2023 results on Oct 05, 2023
お知らせ • Jul 13+ 2 more updatesGerresheimer AG to Report Fiscal Year 2022 Results on Feb 17, 2023Gerresheimer AG announced that they will report fiscal year 2022 results on Feb 17, 2023
お知らせ • Jul 01Gerresheimer AG Updates Its Earnings Guidance for 2026Gerresheimer AG updated its earnings guidance for 2026. Due to the challenging economic environment, some project delays on the part of customers, and operational challenges — among others those related to production ramp-ups — the company is adjusting its guidance for financial year 2026. Before M&A and refinancing activities, the Group now expects revenues to be in the lower half of the EUR 2.3 billion to EUR 2.4 billion range (previously EUR 2.3 billion to EUR 2.4 billion).
お知らせ • Apr 11Gerresheimer AG(XTRA:GXI) dropped from Germany SDAX (Total Return) IndexGerresheimer AG has been dropped from the Germany SDAX (Total Return) Index
お知らせ • Nov 22Gerresheimer AG Announces Supervisory Board ChangesKlaus Röhrig, co-founder and Co-Chief Investment Officer of the Active Ownership Group, has been appointed to the Supervisory Board of Gerresheimer AG until the next Annual General Meeting in June 2026. He succeeds Dr. Dorothea Wenzel, who made her position available to reflect the changed shareholder structure of the company in the composition of the Supervisory Board. With his appointment, Klaus Röhrig also assumes the duties of Dr. Dorothea Wenzel on the Audit Committee of Gerresheimer AG. Klaus Röhrig will stand for election to the Supervisory Board at the next Annual General Meeting on June 3, 2026. In total, four shareholder representatives will be up for election at the next Annual General Meeting of Gerresheimer AG’s co-determined Supervisory Board.
お知らせ • Oct 16+ 3 more updatesGerresheimer AG to Report Fiscal Year 2025 Results on Feb 26, 2026Gerresheimer AG announced that they will report fiscal year 2025 results at 1:25 PM, Central European Standard Time on Feb 26, 2026
お知らせ • Oct 14Gerresheimer Ag Announces Fda Grants Approval of Sq Innovation's Lasix®? OnyuGerresheimer announced that the US Food and Drug Administration (FDA) granted SQ Innovation approval for Lasix ONYU for treatment of edema in congestive heart failure. Lasix ONYU is a combination product consisting of a novel high-concentration formulation of the diuretic furosemide and the Gerresheimer on-body drug delivery device (infusor). It was developed to enable subcutaneous infusion of furosemide at home for selected patients, as prescribed by a clinician without the need for a healthcare professional to administer the drug. The cartridge-based infusor was designed and developed by Gerresheimer based on its proprietary infusor platform for subcutaneous drug delivery. Gerresheimer also manages production of the device as a full-service solution provider. First products of Lasix ONYU are expected to be available on the market already in 2025. The FDA's approval of the combination product demonstrates Gerresheimer's innovative strength and its strong partnership with customers, from product design to large-scale manufacturing. Device based on Gerresheimer's innovative micropump technology: The cartridge-based infus or was designed and developed by Ger Resheimer based on its proprietary infUSor platform for subcutaneous Drug delivery. The core technology is an innovative micropump which enables controlled, precise administration of a drug product according to a defined therapy regimen. Designed with patient comfort and the environment in mind The lightweight, compact device is patched onto the patient's body, making it comfortable for the patient to wear while the drug is gently infused. The reusable component, which is rated for delivery of 48 treatments with diuretic furosemides, is recyclable. Because only the disposable unit requires sterilization, radiation can be used instead of chemical sterilization, and no electronic components end up in medical waste. This two-component concept was developed in line with Gerresheimer's EcoDesign principles, which aim to increase product lifespan and reduce waste. Reducing total cost of care and improving patients' quality of life. The combination product Lasix ONYU also opens up possibilities to reduce the total cost of care. The two-component design results in a lower cost per treatment, because only the disposable part of the device needs to be replaced. Most importantly, the infusor allows for home treatment, reducing the length of hospital stay or avoiding the need for hospitalization for intravenous diuretic administration altogether. First products expected to be available already in 2025 In addition to Gerresheimer's role in design and development, Gerresheimer also manages production the device as a full- service solution provider. The disposable unit for the infusor is, for example, produced at the Gerresheimer facility in Wackersdorf, Germany, on a high-capacity semi-automated line. Production commenced earlier this year in anticipation of approval and first products are expected to be available before the end of the year.
お知らせ • Oct 10+ 2 more updatesGerresheimer AG Appoints Hans-Norbert Topp as Head of Combined Moulded Glass Business UnitGerresheimer AG announced that as part of the integration of Bormioli Pharma into the Gerresheimer Group, Gerresheimer has already begun to establish the combined Moulded Glass business as a global, independent unit. Hans-Norbert Topp, an internationally experienced manager with a proven track record, has been appointed to head the business unit.
お知らせ • Aug 22Active Ownership Wants Review at Gerresheimer After Taking StakeOn August 21, 2025, Active Ownership announced that it saw major potential for value creation at Gerresheimer AG and called for a strategic review. Active Ownership expressly welcomes the planned sale process for the moulded glass division and calls for a swift settlement in order to strengthen the Company's cash flow and reduce debt. Active Ownership also stated that further key measures should include additional portfolio optimization and the implementation of an efficiency programme, particularly through cost reductions in administration and business units. Active Ownership added that this would improve the return on the Company's sales by five percentage points, while also calling for the creation of a strategy committee to review all of the Company's ongoing projects.
お知らせ • Jul 11Gerresheimer AG Provides Revenue Guidance for the Second Half of 2025Gerresheimer AG provided revenue guidance for the second half of 2025. In the second half of 2025, Gerresheimer expects stronger growth again based on production ramp-ups and a good order intake, and anticipates organic revenue growth of 0 – 2% compared to the previous year.
お知らせ • Jun 06Asset Value Investors Calls for Changes at Gerresheimer AGOn June 5, 2025, Asset Value Investors Limited called upon Gerresheimer AG to take steps to restore its market value, a move partially supported by another top 30 investor. Asset Value Investors expressed its views that new financial leadership is needed to restore the Company's relationship and credibility with investors, it said in an open letter to the Company. Asset Value Investors also urged the Company to establish a capital allocation committee and exit its moulded glass business as soon as possible. Union Investment, which holds a 0.9% stake in the Company, said it backed the calls for new leadership and a sale of the moulded glass business but did not see a need for a capital allocation committee.
お知らせ • Jun 05+ 1 more updateGerresheimer AG Revises Earnings Guidance for the Financial Year 2025Gerresheimer AG revised earnings guidance for the financial year 2025. For the financial year, the company expects organic revenue growth to be 1% to 2% compared to the previous year (previously: 3% to 5%).
お知らせ • Apr 24Gerresheimer AG, Annual General Meeting, Jun 05, 2025Gerresheimer AG, Annual General Meeting, Jun 05, 2025, at 10:00 W. Europe Standard Time.
お知らせ • Apr 11Gerresheimer AG Confirms Earnings Guidance for the Mid-Term of the Fiscal Year 2025Gerresheimer AG confirmed earnings guidance for the mid-term of the fiscal year 2025. For the mid-term, the company expects organic revenue growth 8% - 10% CAGR.
お知らせ • Mar 13Warburg Pincus, KKR Consortium Reportedly in Talks to Buy GerresheimerA consortium consisting of Warburg Pincus LLC and KKR & Co. Inc. (NYSE:KKR) are in talks to acquire Gerresheimer AG (ETR:GXI), the German maker of packaging for drugs and cosmetics, according to people familiar with the matter. The private equity firms emerged as the frontrunner after they teamed up and other potential bidders including Bain Capital dropped, the people said, asking not to be identified discussing confidential information. The Warburg Pincus-KKR consortium is unlikely to offer a significant premium to Gerresheimer’s current price and there are still major hurdles to a deal, some of the people said. While the talks are advanced, any final agreement could take weeks and a deal could still fall apart, they added. Representatives for Gerresheimer, Warburg Pincus, KKR and Bain declined to comment.
お知らせ • Feb 27Gerresheimer AG announces Annual dividend, payable on June 10, 2025Gerresheimer AG announced Annual dividend of EUR 1.2500 per share payable on June 10, 2025, ex-date on June 06, 2025 and record date on June 09, 2025.
お知らせ • Feb 21Phillips-Medisize, Bain Capital Reportedly Eye GerresheimerUS medical solutions company Phillips-Medisize (Phillips-Medisize, LLC) and buyout firm Bain Capital (Bain Capital, LP) are among potential bidders for Gerresheimer AG (XTRA:GXI), the German maker of packaging for drugs and cosmetics, according to people familiar with the matter. The firms join other suitors that have been evaluating possible offers for part or all of Gerresheimer, the people said, asking not to be identified because the information is private.
お知らせ • Feb 20Gerresheimer AG to Report Q3, 2025 Results on Oct 10, 2025Gerresheimer AG announced that they will report Q3, 2025 results on Oct 10, 2025
お知らせ • Feb 11Gerresheimer Discussing Takeover with Private Equity InvestorsGerman pill bottles and syringes maker Gerresheimer AG (XTRA:GXI) said on February 07, 2025 that it is in early-stage talks with private equity investors over a potential takeover, confirming a media report. The private equity firms have expressed, on an informal and non-binding basis, their interest to explore a possible public takeover offer for Gerresheimer, the company said. The discussions are still in a very preliminary stage and it is not certain at this point whether an offer will actually be made, the firm added, without disclosing further details. The statement was made after news agency Bloomberg previously reported that private equity firms Warburg Pincus LLC, EQT AB (publ) (OM:EQT) and KKR & Co. Inc. (NYSE:KKR) among other suitors have shown interest in the German pill bottles and syringes maker.
お知らせ • Apr 11Gerresheimer AG Provides Earnings Guidance for the Year 2024 and 2025Gerresheimer AG provided earnings guidance for the year 2024 and 2025. For the year 2024, the company expects revenue growth of 5% to 10%.For the year 2025, the company expects revenue growth of 10% to 15%.
お知らせ • Dec 06+ 1 more updateGerresheimer AG, Annual General Meeting, Jun 05, 2024Gerresheimer AG, Annual General Meeting, Jun 05, 2024.
お知らせ • Oct 06Gerresheimer AG Provides Earnings Guidance for Full Year 2023Gerresheimer AG provided earnings guidance for full year 2023. For the year, the company expects Organic revenue growth: at least 10% and Medium-term guidance (for group level, currency-adjusted), Organic revenue growth: at least 10%.
お知らせ • Sep 28+ 2 more updatesGerresheimer AG to Report Q2, 2024 Results on Jul 11, 2024Gerresheimer AG announced that they will report Q2, 2024 results on Jul 11, 2024
お知らせ • Jul 06Gerresheimer Ag Provides Revenue Guidance for Full Year 2023Gerresheimer AG provided revenue guidance for full year 2023. For the year, the company expects Organic revenue growth: at least 10% and Medium-term guidance (for group level, currency-adjusted), Organic revenue growth: at least 10%.
お知らせ • Jun 08Gerresheimer AG Announces Dividend for the Financial Year 2022, Payable on June 12, 2023Gerresheimer AG announced a dividend of EUR 1.25 for the financial year 2022. The dividend is to be paid out on June 12, 2023.
お知らせ • Dec 28+ 1 more updateGerresheimer AG to Report Q3, 2023 Results on Oct 05, 2023Gerresheimer AG announced that they will report Q3, 2023 results on Oct 05, 2023
お知らせ • Jul 13+ 2 more updatesGerresheimer AG to Report Fiscal Year 2022 Results on Feb 17, 2023Gerresheimer AG announced that they will report fiscal year 2022 results on Feb 17, 2023